- Sections
- C - Chimie; métallurgie
- C07K - Peptides
- C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
Détention brevets de la classe C07K 16/10
Brevets de cette classe: 4728
Historique des publications depuis 10 ans
196
|
272
|
248
|
286
|
295
|
309
|
482
|
596
|
534
|
153
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Propriétaires principaux
Proprétaire |
Total
|
Cette classe
|
---|---|---|
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
129 |
Humabs Biomed SA | 115 |
77 |
Regeneron Pharmaceuticals, Inc. | 3650 |
76 |
Vanderbilt University | 1731 |
69 |
The Scripps Research Institute | 1364 |
68 |
The Rockefeller University | 562 |
64 |
Duke University | 2872 |
57 |
VIR Biotechnology, Inc. | 114 |
45 |
California Institute of Technology | 3884 |
39 |
Dana-Farber Cancer Institute, Inc. | 2455 |
39 |
Institut Pasteur | 798 |
37 |
The Trustees of the University of Pennsylvania | 4122 |
33 |
Academia Sinica | 888 |
33 |
International AIDS Vaccine Initiative | 86 |
33 |
Visterra, Inc. | 110 |
32 |
Janssen Vaccines & Prevention B.V. | 337 |
31 |
MedImmune Limited | 627 |
31 |
The Wistar Institute of Anatomy and Biology | 387 |
31 |
The Trustees of Columbia University in the City of New York | 3440 |
30 |
The Regents of the University of California | 18943 |
28 |
Autres propriétaires | 3746 |